Chardan Capital Issues Positive Estimate for Oculis Earnings

Key Points

• Chardan Capital has raised its FY2025 earnings per share estimate for Oculis to ($2.73), with a price target of $51.00 and maintains a "Buy" rating.
• Oculis stock opened at $21.09, with a 1-year trading range between $14.00 and $23.08, and a market capitalization of $920.79 million.
• Recently, hedge funds have increased their stakes in Oculis, with notable investments from Alyeska Investment Group and Aberdeen Group, reflecting growing interest in the company.

Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities researchers at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for shares of Oculis in a report released on Wednesday, October 8th. Chardan Capital analyst D. Gataulin now anticipates that the company will post earnings per share of ($2.73) for the year, up from their previous estimate of ($2.77). Chardan Capital has a "Buy" rating and a $51.00 price target on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. Chardan Capital also issued estimates for Oculis' FY2026 earnings at ($2.88) EPS.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC assumed coverage on Oculis in a research report on Wednesday, August 27th. They issued a "buy" rating and a $36.00 price target for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oculis in a research report on Wednesday, October 8th. HC Wainwright lifted their target price on Oculis from $33.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, October 7th. Finally, Wall Street Zen lowered Oculis from a "hold" rating to a "sell" rating in a report on Sunday, September 21st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Oculis currently has an average rating of "Moderate Buy" and a consensus price target of $41.00.

Oculis Stock Down 0.2%

Oculis stock opened at $21.09 on Monday. Oculis has a 1-year low of $14.00 and a 1-year high of $23.08. The firm has a market capitalization of $920.79 million, a price-to-earnings ratio of -7.90 and a beta of 0.29. The company has a current ratio of 4.55, a quick ratio of 4.55 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $17.72 and a 200 day simple moving average of $18.08.

Oculis (NASDAQ:OCS - Get Free Report) last posted its earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The business had revenue of $0.25 million during the quarter, compared to analysts' expectations of $0.14 million. Oculis had a negative return on equity of 90.31% and a negative net margin of 13,958.12%.

Hedge Funds Weigh In On Oculis

Hedge funds and other institutional investors have recently modified their holdings of the company. Alyeska Investment Group L.P. purchased a new position in shares of Oculis in the 1st quarter worth about $2,499,000. Kestra Private Wealth Services LLC purchased a new stake in Oculis in the first quarter worth approximately $234,000. Compagnie Lombard Odier SCmA boosted its stake in Oculis by 11.5% in the second quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company's stock worth $1,883,000 after buying an additional 10,000 shares in the last quarter. Aberdeen Group plc boosted its stake in Oculis by 24.1% in the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock worth $23,847,000 after buying an additional 243,695 shares in the last quarter. Finally, Pivotal bioVenture Partners Investment Advisor LLC boosted its stake in shares of Oculis by 32.4% in the 1st quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company's stock valued at $43,784,000 after purchasing an additional 563,078 shares in the last quarter. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.